Hosted on MSN20d
Botox’s biggest rival lands in the US — Leytbo said to be faster-acting and up to 30% cheaper
STAY UP TO DATE WITH THE LATEST NEWS BY SUBSCRIBING TO MORNING REPORT NEWSLETTER In the US, Letybo could give the five other neuromodulartors — Botox, Daxxify, Dysport, Xeomin and Jeuveau — a run for ...
Hosted on MSN11mon
Acorda loses Nasdaq listing to cap biotech’s end
Merz Therapeutics, known for its Botox rival Xeomin (incobotulinumtoxinA), swooped in a day later to buy Acorda’s assets, including Inbrija and Ampyra. Merz acted as a “stalking horse ...